Web Results

www.prnewswire.com/news-releases/seracare-life-sciences-introduces-ivd-labeled-accurun-controls-for-womens-health-231559551.html

Nov 12, 2013 ... 12, 2013 /PRNewswire/ -- SeraCare Life Sciences, a manufacturer of life sciences tools, bulk plasma, and quality controls for diagnostic companies and ... products is an indicator of SeraCare's focus on the Women's Health market," said Vince Smith, director of the Clinical Lab business unit at SeraCare.

www.delawarelitigation.com/2012/04

Apr 11, 2012 ... In ODN Holding Corp., et al., v. Hsu, et al., C. A No. 6790-VCN (March 30, 2012), a dispute arose as to plaintiff Ng's sale of a majority of the common stock (“Stock Sale”) of plaintiff ODN Holding Corporation (“ODN”) to plaintiff Oak Hill ... In Re SeraCare Life Sciences Inc. Shareholders Litigation, C.A. No.

www.seracare.com/en-US/news-events/press-releases/seracare-life-sciences-announces-the-most-patient-like-cfdna-qc-technology

SeraCare Life Sciences Announces the Most Patient-Like cfDNA QC Technology. July 18, 2017. Truth set ctDNA materials to significantly advance the development and validation of liquid biopsy assays. MILFORD, Mass., July 18, 2017 /PRNewswire/ -- SeraCare Life Sciences, a manufacturer and leading partner to global ...

www.seracare.com/en-US/about-us/about-seracare/history

In 2012, Linden Capital Partners acquired SeraCare and introduced our CEO, Charlie Mamrak, and a trusted leadership team who continues to expand SeraCare's specialties for the overall goal of improving the quality of life through a global understanding of disease. The continued development of extreme quality, ...

www.seracare.com/en-US/about-us/contact-us/distribution

Learn more about our worldwide distributor options for SeraCare and KPL- Branded products.

www.ncbi.nlm.nih.gov/pmc/articles/PMC4169399

Sep 18, 2014 ... In 1998, a ground-breaking study by Janssen et al. described the development of a detuned or less-sensitive serologic assay for distinguishing recent .... the range of reactivity for known recent and long-term samples was determined using an HIV-1 Incidence/Prevalence Performance Panel (SeraCare Life ...

journals.plos.org/plosone/article?id=10.1371/journal.pone.0193802

Mar 15, 2018 ... Citation: Plagnol V, Woodhouse S, Howarth K, Lensing S, Smith M, Epstein M, et al. (2018) Analytical .... To assess the InVisionFirst assay's ability to call indels, a custom reference material was created by SeraCare containing eighteen indels targeted by our panel ranging from -24bp to +12bp (S7 Table).

www.pnas.org/content/pnas/103/38/14068.full.pdf

Sep 19, 2006 ... of SeraCare Life Sciences, Inc., Cambridge, MA 02139; iNorthern California Cancer Center, Fremont, CA 94538; jDepartment of Health Research and ..... and assessed how the peak LOD score at 8q24 changes. All seven cohorts contribute positively. Freedman et al. PNAS. September 19, 2006 vol. 103.

www.sciencedirect.com/science/article/pii/S1386653213001923

A recent paper by Ly et al. demonstrated that the sensitivity of currently available commercial assays varied according to HIV genotype and cautioned that this .... Panels were purchased from SeraCare Life Sciences Inc. (Milford, USA; panels PRB958 and PRB930) and North American Biologicals Inc. (Boca Raton, USA; ...